AUTHORS

Real Money authors - Brad Ginesin

Brad Ginesin

Brad Ginesin manages Polar Capital LP, a long/short hedge fund he founded in 2000. He’s worked on and managed several equity trading desks including Monarch Financial and WFP Management. He graduated from Cornell University in 1992 with a degree in Applied Econ & Business Mgmt. Brad is the author of The Trading Desk, a Wall Street inspired novel published in 2021.
Email Brad Ginesin

Recent Articles By The Author

Activision's Microsoft Deal Discount Offers a 'Call of Duty' to Investors

Berkshire Hathaway's involvement and MoffettNathan's case are enough to consider buying in.

Investors, Locked in on Lockheed's Guidance, May Miss Their Shot

Lockheed Martin soared earlier this year and then came spinning downward following earnings, but let's see how this name could fight its way back up.

By George, Here's How Equity Investors Should Play the Almighty Dollar

For the stock market, dollar strength and Fed tightening are the same trade.

Carnival Vs. Delta: Which Is Safer Way for Investors to Travel?

Cruise companies and airlines are trading well below their pre-pandemic prices, with Delta and Carnival showing potential promise as travel returns.

Upstart Looks Like a Downer, but Should We Give It a Second Chance?

A weakened economy and bear market have exposed trouble at this artificial intelligence-driven consumer lending company.

3M Looks Like a Clean Bargain, Until You Realize a Dirty Truth

It's unclear how costly cleanup and legal battles over PFAS will be for this iconic American company.

We Can't Predict the Rest of 2022, but We Must Have a Game Plan

Many are forecasting bad times ahead, but are they going to extremes? Here's my strategy for the the second half of the year.

Let's Shine a Light on Lucid Motors as It Slides Downhill

LCID's market cap has been deflated, so is it now a bargain, or can it slip further?

Feeling Queasy Over Moderna's Outlook? Investors May Still Get Their Shot

With an expected dip for 2023, the pharmaceutical company could see its mRNA technology win big over the long term -- and investors could be rewarded.

The Best House in This Neighborhood Is on Sale

The buying opportunity here below book value is compelling.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight